# SENATE COMMITTEE AMENDMENTS

2022 Regular Session

Amendments proposed by Senate Committee on Insurance to Original Senate Bill No. 118 by Senator Talbot

### AMENDMENT NO. 1

On page 1, line 2, after "R.S. 22:1028.3(B)(2)" insert "and to enact R.S. 22:1028.3(D)(3) and (4),"

# AMENDMENT NO. 2

On page 1, line 5, after "guidelines;" insert "to provide definitions;"

#### AMENDMENT NO. 3

On page 1, line 7, after "reenacted" insert "and R.S. 22:1028.3(D)(3) and(4) are hereby enacted"

#### AMENDMENT NO. 4

On page 1, delete lines 12 through 17 and insert the following:

"established under the health plan. <u>The biomarker test shall be covered for the</u> <u>purposes of diagnosis, treatment, appropriate management or ongoing</u> <u>monitoring of an individual's disease or condition when the test is supported by</u> <u>medical and scientific evidence, including but not limited to the following:</u>

(a) Labeled indications for tests are approved or cleared by the United States Food and Drug Administration or indicated tests for a drug that is approved by the United States Food and Drug Administration.

(b) Centers for Medicare and Medicaid Services National Coverage Determinations or Medicare Administrative Contractor Local Coverage Determinations.

(c) Nationally recognized clinical practice guidelines and consensus statements.

\*

D. As used in this Section, the following definitions shall apply unless the context indicates otherwise:

(1) \* \* \*

(3) "Consensus statements" means statements developed by an independent, multidisciplinary panel of experts utilizing a transparent methodology and reporting structure and with a conflict-of-interest policy and these statements are aimed at specific clinical circumstances and base the statements on the best available evidence for the purposes of optimizing the outcomes of clinical care.

(4) "Nationally recognized clinical practice guidelines" means evidencebased clinical guidelines developed by independent organizations or medical professional societies utilizing a transparent methodology and reporting structure and with a conflict-of-interest policy and clinical guidelines establish standards of care informed by a systematic review of evidence and an assessment of the benefits and costs alternative care options and include recommendations intended to optimize patient care."